SEC Form 4Coverage since Jun 16, 2025Open-market trades only
$RVMD insider trading
Over the last 12 months, Revolution Medicines insiders reported no purchases and 53 sales totaling $127.5M across SEC Form 4 filings. 98% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $127.5M 53 events
- Events · 12m
- 53 Form 4 filings, grouped
- Insiders · 12m
- 10 distinct reporters
- 10b5-1 share
- 98% of events, not dollars
Side
Price · $RVMD · 3Mvia TradingView
Top insiders · 12m
GOLDSMITH MARK ASee Remarks15× · $54.8M
Cislini JeffGeneral Counsel9× · $14.6M
Anders JackChief Financial Officer8× · $6.4M
Kelsey Stephen MichaelSee Remarks6× · $8.5M
Horn Margaret AChief Operating Officer6× · $25.0M
All insider trades
50 of 54 events
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 31, 2026 | Kim Lorence H.D | ▼ Sale | 56,000 | $203.24 | $11.4M | -76.6% | plan · 7 tranches · indirect |
| Aug 21, 2026 | Cislini JeffGeneral Counsel · O | ▼ Sale | 56,894 | $209.24 | $11.9M | -50.4% | plan · 6 tranches |
| Aug 21, 2026 | GOLDSMITH MARK ASee Remarks · O·D | ▼ Sale | 6,000 | $209.2 | $1.3M | -8.9% | plan · 12 tranches · indirect |
| Aug 21, 2026 | GOLDSMITH MARK ASee Remarks · O·D | ▼ Sale | 80,000 | $209.2 | $16.7M | -23% | plan · 6 tranches |
| Jun 29, 2026 | Patel SushilD | ▼ Sale | 5,580 | $187.99 | $1.0M | -20.5% | plan · 9 tranches |
| Jun 24, 2026 | Anders JackChief Financial Officer · O | ▼ Sale | 20,000 | $168.33 | $3.4M | -14% | plan · 4 tranches |
| Jun 17, 2026 | Horn Margaret AChief Operating Officer · O | ▼ Sale | 93,575 | $160 | $15.0M | -37.7% | plan · 3 tranches |
| Jun 16, 2026 | Anders JackChief Financial Officer · O | ▼ Sale | 2,722 | $156.12 | $425K | -2.2% | plan |
| Jun 16, 2026 | Kelsey Stephen MichaelSee Remarks · O | ▼ Sale | 4,175 | $156.12 | $652K | -1.4% | plan |
| Jun 16, 2026 | Mancini AnthonySee Remarks · O | ▼ Sale | 4,615 | $156.12 | $720K | -8.5% | — |
| Jun 16, 2026 | GOLDSMITH MARK ASee Remarks · O·D | ▼ Sale | 10,020 | $156.12 | $1.6M | -3.6% | plan |
| Jun 16, 2026 | Cislini JeffGeneral Counsel · O | ▼ Sale | 2,157 | $156.12 | $337K | -3.7% | plan |
| Jun 11, 2026 | Horn Margaret AChief Operating Officer · O | ▼ Sale | 10,000 | $148.01 | $1.5M | -5.9% | plan · 7 tranches |
| May 26, 2026 | Mancini AnthonySee Remarks · O | ▼ Sale | 3,121 | $153.99 | $481K | -5.4% | plan · 3 tranches |
| Apr 27, 2026 | Mancini AnthonySee Remarks · O | ▼ Sale | 3,120 | $132.41 | $413K | -5.4% | plan · 3 tranches |
| Apr 15, 2026 | GOLDSMITH MARK ASee Remarks · O·D | ▼ Sale | 120,000 | $150.09 | $18.0M | -30.2% | plan |
| Mar 25, 2026 | Mancini AnthonySee Remarks · O | ▼ Sale | 37,450 | $95.56 | $3.6M | -40.8% | plan · 5 tranches |
| Mar 19, 2026 | Cislini JeffGeneral Counsel · O | ▼ Sale | 2,958 | $98.68 | $292K | -4.8% | plan · 2 tranches |
| Mar 17, 2026 | Wei LinChief Medical Officer · O | ▼ Sale | 2,073 | $99.48 | $206K | -2% | plan |
| Mar 17, 2026 | Kelsey Stephen MichaelSee Remarks · O | ▼ Sale | 4,302 | $99.48 | $428K | -1.4% | plan |
| Mar 17, 2026 | GOLDSMITH MARK ASee Remarks · O·D | ▼ Sale | 12,871 | $99.48 | $1.3M | -4.4% | plan |
| Mar 17, 2026 | Horn Margaret AChief Operating Officer · O | ▼ Sale | 4,583 | $99.48 | $456K | -2.8% | plan |
| Mar 17, 2026 | Anders JackChief Financial Officer · O | ▼ Sale | 2,753 | $99.48 | $274K | -2.1% | plan |
| Mar 17, 2026 | Wang XiaolinSee Remarks · O | ▼ Sale | 2,010 | $99.48 | $200K | -1.7% | plan |
| Mar 2, 2026 | GOLDSMITH MARK ASee Remarks · O·D | ▼ Sale | 6,000 | $101.3 | $608K | -8.5% | plan · 8 tranches · indirect |
| Mar 2, 2026 | GOLDSMITH MARK ASee Remarks · O·D | ▼ Sale | 30,000 | $101.22 | $3.0M | -9.4% | plan · 5 tranches |
| Jan 21, 2026 | Cislini JeffGeneral Counsel · O | ▼ Sale | 908 | $115.6 | $105K | -1.9% | plan |
| Jan 7, 2026 | Horn Margaret AChief Operating Officer · O | ▼ Sale | 75,000 | $100.56 | $7.5M | -34.7% | plan · 3 tranches |
| Jan 7, 2026 | Anders JackChief Financial Officer · O | ▼ Sale | 10,000 | $98 | $980K | -8.5% | plan |
| Dec 16, 2025 | Cislini JeffGeneral Counsel · O | ▼ Sale | 2,688 | $76.82 | $206K | -5.3% | plan |
| Dec 16, 2025 | GOLDSMITH MARK ASee Remarks · O·D | ▼ Sale | 15,394 | $76.82 | $1.2M | -6.2% | plan |
| Dec 16, 2025 | Kelsey Stephen MichaelSee Remarks · O | ▼ Sale | 5,447 | $76.82 | $418K | -1.9% | plan |
| Dec 16, 2025 | Horn Margaret AChief Operating Officer · O | ▼ Sale | 4,847 | $76.82 | $372K | -3.3% | plan |
| Dec 16, 2025 | Anders JackChief Financial Officer · O | ▼ Sale | 3,104 | $77.09 | $239K | -2.8% | plan |
| Nov 25, 2025 | Anders JackChief Financial Officer · O | ▼ Sale | 5,418 | $74 | $401K | -4.7% | plan |
| Nov 25, 2025 | GOLDSMITH MARK ASee Remarks · O·D | ▼ Sale | 6,000 | $75 | $450K | -8.2% | plan · 2 tranches · indirect |
| Nov 25, 2025 | GOLDSMITH MARK ASee Remarks · O·D | ▼ Sale | 60,000 | $75.08 | $4.5M | -19.5% | plan |
| Nov 18, 2025 | GOLDSMITH MARK ASee Remarks · O·D | ▼ Sale | 20,000 | $70.38 | $1.4M | -7.5% | plan |
| Nov 18, 2025 | Cislini JeffGeneral Counsel · O | ▼ Sale | 13,388 | $70.14 | $939K | -21% | plan |
| Nov 12, 2025 | GOLDSMITH MARK ASee Remarks · O·D | ▼ Sale | 20,000 | $65.07 | $1.3M | -7.5% | plan |
| Nov 11, 2025 | Anders JackChief Financial Officer · O | ▼ Sale | 10,000 | $64 | $640K | -8.3% | plan |
| Nov 7, 2025 | GOLDSMITH MARK ASee Remarks · O·D | ▼ Sale | 30,000 | $60.31 | $1.8M | -7.9% | plan |
| Oct 17, 2025 | Cislini JeffGeneral Counsel · O | ▼ Sale | 12,000 | $55 | $660K | -19.2% | plan |
| Oct 17, 2025 | GOLDSMITH MARK ASee Remarks · O·D | ▼ Sale | 20,000 | $52.74 | $1.1M | -4.2% | plan · 2 tranches |
| Oct 13, 2025 | Kelsey Stephen MichaelSee Remarks · O | ▼ Sale | 25,000 | $48.54 | $1.2M | -8.1% | plan |
| Sep 24, 2025 | Cislini JeffGeneral Counsel · O | ▼ Sale | 1,799 | $44.26 | $80K | -3.4% | plan |
| Sep 16, 2025 | Wei LinChief Medical Officer · O | ▼ Sale | 2,160 | $45.82 | $99K | -2.4% | plan |
| Sep 16, 2025 | Kelsey Stephen MichaelSee Remarks · O | ▼ Sale | 5,367 | $45.82 | $246K | -1.9% | plan |
| Sep 16, 2025 | GOLDSMITH MARK ASee Remarks · O·D | ▼ Sale | 13,411 | $45.82 | $615K | -2.9% | plan |
| Sep 16, 2025 | Horn Margaret AChief Operating Officer · O | ▼ Sale | 4,775 | $45.82 | $219K | -3.2% | plan |
Every $RVMD filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Revolution Medicines filings can reach your inbox instead.
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $RVMD feed.